Innovative Biomarkers in de Novo Parkinson's Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Healthy Controls Group - Age and Sex-matched
- Parkinson's Disease
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 30 years and 125 years
- Gender
- Both males and females
Description
The investigators will use 4 different approaches in parallel: detailed clinical evaluation using the current available validated clinical scales and the Dopamine transporter (DAT) SPECT imaging; anatomical and perfusional brain evaluation using functional MRI; cortical brain mapping and transcrania...
The investigators will use 4 different approaches in parallel: detailed clinical evaluation using the current available validated clinical scales and the Dopamine transporter (DAT) SPECT imaging; anatomical and perfusional brain evaluation using functional MRI; cortical brain mapping and transcranial magnetic stimulation assessment using a robotized approach; emotional responses study using a novel paradigm. These 4 modalities will be assessed at baseline, 1 year and 2 years follow-up. The investigators will integrate these 4 analysis using a mathematical paradigm in order to define specific phenotype of disease and disease progression.
Tracking Information
- NCT #
- NCT03940677
- Collaborators
- University Hospital, Clermont-Ferrand
- Grenoble Institut des Neurosciences
- Investigators
- Principal Investigator: Elena Moro, MD, PhD CHU Grenoble Alpes
Get Well Soon